A triple medication combination could be life-changing for the majority of patients with cystic fibrosis.
Patients with cystic fibrosis show transcriptomic changes after starting treatment with lumacaftor/ivacaftor.
Treated immune cells function properly to kill more bacteria, depending on the treatment and the bacteria.
A retrospective chart review suggests early spirometry is associated with shorter length of stay.
A study finds that CFTR mutation analysis is being ordered before (or without) sweat chloride in some cases, potentially leading to missed diagnoses, increased patient anxiety and unnecessary costs.
